May 13, 2020 / 8:23 AM / in 14 days

BRIEF-Oasmia Pharmaceutical: Outcome Of Strategic Review To Deliver Long-Term, Profitable Growth As A Specialty Pharma Company

May 13 (Reuters) - Oasmia Pharmaceutical AB:

* ANNOUNCES OUTCOME OF STRATEGIC REVIEW TO DELIVER LONG-TERM, PROFITABLE GROWTH AS A SPECIALTY PHARMA COMPANY

* WILL UNDERTAKE A COMPREHENSIVE COST CONTROL PROGRAM

* KEY ASPECTS OF THE COST CONTROL PROGRAM INCLUDE: ANNUALISED COST SAVINGS OF MORE THAN SEK 100 MILLION

* KEY ASPECTS OF THE COST CONTROL PROGRAM INCLUDE: ABOUT 50% REDUCTION IN THE CASH BURN RATE TO BELOW SEK 10 MILLION A MONTH

* KEY ASPECTS OF COST CONTROL PROGRAM INCLUDE: GREATER FOCUS ON RESEARCH AND DEVELOPMENT AND CLINICAL TRIAL GMP MANUFACTURING AS OPPOSED TO COMMERCIAL MANUFACTURING Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below